Endocrine Abstracts

While the importance of fibroblast growth factor 23 (FGF-23) is established in the pathogenesis of phosphate wasting disorders, little is known about the mechanisms regulating its circulating level. To investigate the role of parathyroid hormone (PTH) in FGF-23 homeostasis, cinacalcet hydrochloride, a calcimimetic compound to suppress PTH secretion, was administered to the patients with primary hyperparathyroidism (PHPT). Fourteen patients with PHPT, who met the guidelines of ...

UX023-CL303 is an ongoing, Phase 3, double-blind, multicenter study examining the efficacy and safety of burosumab, a fully human monoclonal antibody against FGF23, in adults with XLH. Eligible subjects had serum phosphorus levels <0.81 mmol/l and skeletal pain (BPI – Worst Pain ≥4). Subjects (N=134) were randomized 1:1 to receive burosumab 1 mg/kg or placebo subcutaneously every 4 weeks. After 24 weeks, subjects in the placebo group crossed-over to rec...

Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH). Individuals with chronic hypoparathyroidism managed with conventional therapy (active vitamin D and calcium) are at increased risk for renal complications and declines in renal function. In clinical trials, palopegteriparatide treatment enabled independence from conventional therapy (no active vitamin D and ≤600 mg/day elemental calcium) and maintained serum biochemistr...